Literature DB >> 31362295

Loop Diuretics in Acute Kidney Injury Prevention, Therapy, and Risk Stratification.

Daniel Patschan1, Susann Patschan2, Ivo Buschmann2, Oliver Ritter2.   

Abstract

BACKGROUND: Loop diuretics (LD) are widely used in emergency and intensive care medicine.
SUMMARY: The substances increase the clearance of electrolytes and water; thus, they allow us to control hypervolemia and to prevent patients from pulmonary edema. LD are also frequently applied to patients with an acute decrease in glomerular filtration rate, namely, acute kidney injury (AKI). Nevertheless, volume depletion may be associated with reduced renal perfusion and possibly slower restitution or even aggravation of kidney dysfunction. Several trials on the preventive or therapeutic efficacy of LD have been published since the early 1970s. Our review article is intended to summarize the most important references related to this topic. In addition, we discuss the diagnostic value of the so-called furosemide stress test. The currently available data indicate that LD may act in a beneficial manner as long as euvolemia is maintained (matched hydration). Key Massages: LD are not beneficial for AKI treatment if kidney-related endpoints are considered. In certain situations, AKI prevention with LD can be associated with favorable outcomes as long as euvolemia is maintained. LD can help to identify AKI subjects at a higher risk of AKI progression, but the exact clinical consequences need to be determined.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Loop diuretics; Prevention; Risk stratification; Therapy

Year:  2019        PMID: 31362295     DOI: 10.1159/000501315

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  8 in total

1.  Antihypertensive Treatment in Kidney Transplant Recipients-A Current Single Center Experience.

Authors:  Ulrich Jehn; Katharina Schütte-Nütgen; Markus Strauss; Jan Kunert; Hermann Pavenstädt; Gerold Thölking; Barbara Suwelack; Stefan Reuter
Journal:  J Clin Med       Date:  2020-12-07       Impact factor: 4.241

Review 2.  Acute kidney injury.

Authors:  John A Kellum; Paola Romagnani; Gloria Ashuntantang; Claudio Ronco; Alexander Zarbock; Hans-Joachim Anders
Journal:  Nat Rev Dis Primers       Date:  2021-07-15       Impact factor: 52.329

3.  Risk Factors and Outcomes of Acute Kidney Injury in Critically Ill Patients with Coronavirus Disease 2019.

Authors:  Yichun Cheng; Nanhui Zhang; Ran Luo; Meng Zhang; Zhixiang Wang; Lei Dong; Junhua Li; Rui Zeng; Ying Yao; Shuwang Ge; Gang Xu
Journal:  Kidney Dis (Basel)       Date:  2020-10-26

4.  Association Between Furosemide Exposure and Clinical Outcomes in a Retrospective Cohort of Critically Ill Children.

Authors:  Xiaomei Dai; Jiao Chen; Wenjing Li; Zhenjiang Bai; Xiaozhong Li; Jian Wang; Yanhong Li
Journal:  Front Pediatr       Date:  2021-01-25       Impact factor: 3.418

5.  Risk factors for and characteristics of community- and hospital-acquired drug-induced acute kidney injuries.

Authors:  Amayelle Rey; Valérie Gras-Champel; Gabriel Choukroun; Kamel Masmoudi; Sophie Liabeuf
Journal:  Fundam Clin Pharmacol       Date:  2022-01-25       Impact factor: 2.747

Review 6.  Future insights of pharmacological prevention for AKI post cardiopulmonary bypass surgery (based on PK/PD approach).

Authors:  Dias Permeisari
Journal:  Front Pharmacol       Date:  2022-09-22       Impact factor: 5.988

Review 7.  Strategies to reduce the risk of platinum containing antineoplastic drug-induced ototoxicity.

Authors:  Debashree Mukherjea; Asmita Dhukhwa; Amit Sapra; Priyanka Bhandari; Katlyn Woolford; Jacob Franke; Vickram Ramkumar; Leonard Rybak
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-09-29       Impact factor: 4.481

8.  Clinical significance of frusemide stress test in predicting the severity of acute kidney injury.

Authors:  Arun Gokul Pon; Raveendran Vairakkani; Edwin Fernando Mervin; Nagalakshmi Dhanapal Srinivasaprasad; Thirumalvalavan Kaliaperumal
Journal:  J Bras Nefrol       Date:  2021 Oct-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.